Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Chuikyo OKs Measures Proposed by Korosho to Promote Use of Generics
January 4, 2010
- Novo Nordisk Starts PI for Oral Insulin Analogue in Germany
January 4, 2010
- Premium Decided at 80% of Korosho Proposal, Long-Listed Products to See 2.2% Price Cut
January 4, 2010
- PII of Riociguat for PH-ILD, PH-COPD Completed: Bayer
January 4, 2010
- Ethical Drugs Sales Up 6.2% Driven by Flu Vaccines: Crecon
January 4, 2010
- MOF Demands Double-Digit Cut in Prices of Long-Listed Drugs
January 4, 2010
- NIBIO to Start Supplying iPS Cells to Private Companies
January 4, 2010
- Takeda Licenses Brentuximab from Seattle Genetics
January 4, 2010
- Health Minister Optimistic about Increases in Medical Fees after Tete-a-Tete with Finance Minister
January 4, 2010
- Carna Biosciences’Colon Cancer Research Project Subsidized by JST
January 4, 2010
- Astellas Licenses FLT3 Inhibitors from Ambit Biosciences
January 4, 2010
- Victoza, Bridion Recommended for Approval
January 4, 2010
- Chuikyo Recommends Approval of Proposed System Reform for Insurance-Covered Medical Materials
January 4, 2010
- DSP Undertakes Sweeping Reorganization to Enhance Its Presence in CNS Field
January 4, 2010
- New Premium Intended to Strengthen Japanese Pharmas: Mr Kinoshita
January 4, 2010
- CMIC Licenses L-FABP to Roche
January 4, 2010
- Takeda to Copromote Actos with Pfizer in China
January 4, 2010
- Chuikyo Recommends Unification of Revisit Consultation Fee for Clinics and Hospitals
January 4, 2010
- IBL Launches Human Amyloidβ (1-38) Assay Kit
January 4, 2010
- AZ Aims at Top Share for Asthma with Symbicort
January 4, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…